John L. Brottem - Feb 16, 2023 Form 4 Insider Report for Outset Medical, Inc. (OM)

Signature
John L Brottem
Stock symbol
OM
Transactions as of
Feb 16, 2023
Transactions value $
-$159,284
Form type
4
Date filed
2/17/2023, 03:15 PM
Previous filing
Jan 30, 2023
Next filing
Mar 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OM Common Stock Options Exercise $21.5K +2.27K +3.41% $9.48 68.7K Feb 16, 2023 Direct
transaction OM Common Stock Sale -$54.3K -2.27K -3.3% $23.96 66.4K Feb 16, 2023 Direct F1
transaction OM Common Stock Options Exercise $26.8K +2.83K +4.26% $9.48 69.3K Feb 16, 2023 Direct
transaction OM Common Stock Sale -$67.8K -2.83K -4.09% $23.96 66.4K Feb 16, 2023 Direct F1
transaction OM Common Stock Sale -$85.5K -3.53K -5.32% $24.22 62.9K Feb 16, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OM Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.83K -11.11% $0.00 22.6K Feb 16, 2023 Common Stock 2.83K $9.48 Direct F2
transaction OM Performance Options (right to buy) Options Exercise $0 -2.27K -100% $0.00* 0 Feb 16, 2023 Common Stock 2.27K $9.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from: $23.00-$23.99 - 3,486 shares; $24.00-$24.99 - 1,608 shares. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 This option vests 25% on May 26, 2021 and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F3 In March 2021, following the expiration of the lock-up period in connection with our initial public offering, the applicable performance and market-based vesting conditions were met and the shares underlying this stock option award became fully vested.